Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published August 3, 2022 | Published
Journal Article Open

5-HT₃ Receptor MX Helix Contributes to Receptor Function

Abstract

5-HT₃ receptors are members of the family of pentameric ligand-gated ion channels. Each subunit has an extracellular, transmembrane, and intracellular domain. Only part of the intracellular domain structure has been solved, revealing it contains two α-helical segments; one, the MA helix, is an extension of M4, while the other, the MX helix, is formed from residues located close to the end of M3. This MX helix is in distinct locations in open and closed receptor structures, suggesting it may play a role in function. Here, we explore this hypothesis using functional responses of Ala-substituted mutant receptors expressed in HEK293 cells. The data show altering many of the MX residues results in a small decrease in EC50 (up to 5-fold), although in one (H232A) this is increased. Radiolabeled ligand binding on selected mutants showed no change in binding affinity, indicating an effect on gating and not binding. In addition, five mutations (P316A, V317A, P318A, D319A, and H323A) initially resulted in nonfunctional receptors, but the function could be rescued by coexpression with a chaperone protein, suggesting a likely role in assembly or folding. Examination of previously obtained MD simulation data shows that the extent of MX encompassed by membrane lipids differs considerably in the open and closed structures, suggesting that lipid–protein interactions in this region could have a major effect on channel opening propensity. We conclude that the MX helix can modulate the function of the receptor and propose that its interactions with membrane lipids play a major role in this.

Additional Information

© 2022 The Authors. Published by American Chemical Society. Attribution 4.0 International (CC BY 4.0). Received 10 June 2022. Accepted 6 July 2022. Published online 22 July 2022. S.M. was supported by an AstraZeneca studentship. S.C.R.L. was supported by the MRC (MR/L021676/1). Author Contributions. Participated in research design: S.C.R.L. Conducted experiments and data analysis: J.M., S.M., and S.C.R.L. Designed and provided reagents: D.A.D. The authors declare no competing financial interest.

Attached Files

Published - cn2c00339.pdf

Files

cn2c00339.pdf
Files (6.5 MB)
Name Size Download all
md5:5df34261495e9c6c97f7fcae419a8b8e
6.5 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 24, 2023